#1 Clinical Trials Search in Europe

Dfv890

DFV890 is an investigational drug being studied in clinical trials for its potential to treat a variety of medical conditions. These trials aim to evaluate the safety, efficacy, and tolerability of DFV890 in patients with different diseases, including familial cold auto-inflammatory syndrome (FCAS), myeloid diseases, knee osteoarthritis, coronary heart disease, and COVID-19 pneumonia. The studies explore various dosing regimens and compare DFV890 to placebo or standard of care treatments.

Table of Contents

What is DFV890?

DFV890 is an investigational drug currently being studied for its potential to treat various medical conditions. It is a new medication that is taken orally (by mouth) in the form of tablets[1][2]. Researchers are exploring its effectiveness in reducing inflammation and managing symptoms associated with several diseases.

What Conditions Does DFV890 Treat?

Based on ongoing clinical trials, DFV890 is being investigated for the treatment of several conditions:

  • Myeloid Diseases: These are disorders affecting blood cells. DFV890 is being studied in patients with lower-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)[1].
  • Familial Cold Autoinflammatory Syndrome (FCAS): This is a rare genetic condition that causes episodes of inflammation in response to cold temperatures[2].
  • Knee Osteoarthritis: A common form of arthritis that causes pain and stiffness in the knee joints[3].
  • Coronary Heart Disease: A condition where the arteries supplying blood to the heart become narrowed or blocked[4][5].
  • COVID-19 Pneumonia: Lung inflammation caused by the SARS-CoV-2 virus[6].

How Does DFV890 Work?

While the exact mechanism of action is not fully explained in the provided information, DFV890 appears to target inflammation in the body. It is being studied for its ability to reduce levels of inflammatory markers such as interleukin-6 (IL-6) and interleukin-18 (IL-18)[4][5]. These are proteins in the body that play a role in the inflammatory process. By reducing inflammation, DFV890 may help alleviate symptoms and improve outcomes in various conditions.

How is DFV890 Administered?

DFV890 is typically administered as oral tablets. The dosage and frequency may vary depending on the condition being treated:

  • For some studies, it is given twice daily[2].
  • In other trials, the dose may be adjusted or increased over time to find the most effective and safe dose[4][5].
  • For COVID-19 pneumonia, it was studied at a dose of 50 mg twice per day for 14 days[6].

Current Clinical Trials

DFV890 is currently being evaluated in several clinical trials:

  • A study for myeloid diseases to assess its safety, effectiveness, and optimal dosage[1].
  • A trial for Familial Cold Autoinflammatory Syndrome to evaluate its ability to reduce inflammation triggered by cold exposure[2].
  • An investigation for knee osteoarthritis to determine if it can reduce pain and improve joint function[3].
  • Studies in patients with coronary heart disease to assess its impact on reducing inflammation markers[4][5].
  • A completed study in patients with COVID-19 pneumonia to evaluate its potential in improving respiratory function and reducing disease severity[6].

Potential Side Effects

As DFV890 is still in the investigational stage, the full range of potential side effects is not yet known. Clinical trials are designed to assess both the effectiveness and safety of the drug. Researchers are monitoring for any adverse events (side effects) that may occur during the studies[2][3]. It’s important to note that all medications can have side effects, and the benefits and risks must be carefully weighed for each individual patient.

If you’re considering participating in a clinical trial or have questions about DFV890, it’s crucial to discuss this with your healthcare provider. They can provide more information about the potential benefits and risks based on your specific medical condition and health status.

Condition Study Phase Key Outcomes Measured Administration
Familial Cold Auto-inflammatory Syndrome (FCAS) Phase II White blood cell count changes, physician and patient assessments Oral tablets, 100 mg twice daily for 3 days, then 100 mg on day 4
Myeloid Diseases Phase Ib Dose-limiting toxicities, transfusion independence, hematological improvements Oral tablets, dose optimization study
Knee Osteoarthritis Phase II KOOS pain subscale, synovitis activity, serum inflammatory markers Oral tablets, dosing not specified
Coronary Heart Disease with elevated hsCRP Phase IIa Serum levels of IL-6 and IL-18, pharmacokinetics Oral tablets, dose escalation over 12 weeks
COVID-19 Pneumonia Phase II APACHE II score, C-reactive protein levels, clinical status Oral/nasogastric, 50 mg twice daily for 14 days

FAQ

  • What conditions is DFV890 being studied for? DFV890 is being investigated for several conditions, including familial cold auto-inflammatory syndrome (FCAS), myeloid diseases, knee osteoarthritis, coronary heart disease, and COVID-19 pneumonia.
  • How is DFV890 administered in these trials? DFV890 is typically administered orally as tablets. The dosing regimens vary depending on the study, ranging from twice daily dosing to once daily dosing for different durations.
  • What are the main goals of these clinical trials? The main goals of these trials are to assess the safety, efficacy, and tolerability of DFV890 in treating various conditions. They also aim to determine optimal dosing and evaluate the drug's effects on specific disease markers and symptoms.
  • Are there any side effects associated with DFV890? The trials are designed to monitor for adverse events and serious adverse events. However, specific side effects are not detailed in the provided information. Safety assessments are a key component of all the studies.
  • How long do these clinical trials typically last? The duration of the trials varies. Some last for a few weeks, while others extend up to several months. For example, the knee osteoarthritis study lasts up to 21 weeks, while the COVID-19 pneumonia study has a 29-day observation period followed by a 30-day safety follow-up.

Ongoing Clinical Trials on Dfv890

  • Study on DFV890 and MAS825 for Reducing Inflammation in Adults with Coronary Heart Disease and Clonal Hematopoiesis

    Not recruiting

    1
    Investigated drugs:
    Germany

  • Study on the Effects of DFV890 for Pain Relief in Patients with Knee Osteoarthritis

    Not recruiting

    1 1
    Investigated drugs:
    Czechia Germany Hungary Romania Spain

Glossary

  • Familial Cold Auto-inflammatory Syndrome (FCAS): A rare inherited condition characterized by recurrent episodes of fever, rash, and joint pain triggered by exposure to cold temperatures.
  • Myeloid Diseases: A group of blood disorders affecting the production and function of blood cells, particularly those derived from myeloid stem cells.
  • Osteoarthritis: A degenerative joint disease characterized by the breakdown of cartilage in joints, leading to pain, stiffness, and reduced mobility.
  • Coronary Heart Disease: A condition where the blood vessels supplying the heart become narrowed or blocked, often leading to chest pain, shortness of breath, or heart attacks.
  • Clonal Hematopoiesis of Indeterminate Potential (CHIP): A condition where blood stem cells develop genetic mutations associated with blood cancers, but without causing disease.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Efficacy: The ability of a drug or treatment to produce the desired beneficial effect.
  • Placebo: An inactive substance or treatment used in clinical trials to compare the effects of a drug against a control group.
  • Standard of Care (SoC): The currently accepted treatment or best practice for a specific condition, used as a comparison in clinical trials.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT05552469
  2. https://clinicaltrials.gov/study/NCT04868968
  3. https://clinicaltrials.eu/trial/study-on-the-effects-of-dfv890-for-pain-relief-in-patients-with-knee-osteoarthritis/
  4. https://clinicaltrials.gov/study/NCT06031844
  5. https://clinicaltrials.gov/study/NCT06097663
  6. https://clinicaltrials.gov/study/NCT04382053